Study: NCT06007911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5 mg/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Description: 20 mg/m\^2 subcutaneous days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Description: 20 mg/m\^2 subcutaneous days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Description: 20 mg/m\^2 subcutaneous days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Description: 20 mg/m\^2 subcutaneous days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Cladribine Low Dose Cytarabine Backbone)
Description: 20 mg/m\^2 subcutaneous days 1-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (CLAG-M Backbone)
Description: 1.5 g/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (CLAG-M Backbone)
Description: 1.5 g/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (CLAG-M Backbone)
Description: 1.5 g/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (CLAG-M Backbone)
Description: 1.5 g/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (CLAG-M Backbone)
Description: 1.5 g/m\^2 intravenously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 intravenously days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 intravenously days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 intravenously days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 intravenously days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 intravenously days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300 mcg subcutaneously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300 mcg subcutaneously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300 mcg subcutaneously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300 mcg subcutaneously days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 300 mcg subcutaneously days 1-5.